Now and in the future, innovation-driven has become the will of the nation. The pharmaceutical industry will return to the essence of the industry. A comprehensive analysis of outstanding enterprises in the past decade may be more instructive to the development of the industry and the growth of enterprises.
R&d and innovation are the core drivers
China's pharmaceutical market has experienced four stages: shortage and supply, balance and surplus, imitation and pursuit, innovation and upgrading. In the early days of the founding of the People's Republic of China, China's pharmaceutical products and services were in short supply for a long time. At this stage, the production-oriented enterprises with a large production system and the ability to do large-scale production became the industry leaders. From 1985 to 2000, with the entry of private and foreign enterprises, the shortage of supply has gradually changed to the balance of supply and demand or even excess supply. Homogenization competition has intensified, and marketing oriented enterprises with a large marketing system have begun to rise. From 2000 to 2014, the leading pharmaceutical companies in China started to take generic drugs as the starting point, taking the first imitation medicine as the core product, realizing technology accumulation and upgrading in imitation, and gradually forming the r&d innovation capacity. Now and in the future, innovation-driven has become the national will, the pharmaceutical industry will return to the essence of the industry, drug innovation will gradually become the core growth point of the industry, and scientific and technological innovation will become the main driving force for enterprise development.
In terms of policy, in recent years, encouraging innovation has become one of the main directions of the reform of the pharmaceutical industry, encouraging innovation through multiple links such as review and approval, medical insurance payment and so on. Refine the process of review and approval, and give priority to the examination and approval of innovative drugs. As of mid-july, the pharmaceutical examination center has published a list of 30 batches of priority reviews. Mode of innovative drugs through the national price negotiations into coverage, there are 36 negotiations in 2017 varieties include health insurance directory, such as injection with urokinase of restructuring the original of tasly, xinli tai temple, sand ester piece, hengrui pharmaceutical mesylate path for piece, yasuhiro miyata pharmaceutical compaq heap, sail medicine compound Huang Dai piece etc, and the national health insurance bureau is to plan as a whole in 2018 cancer drugs health care access specific negotiations.
From the perspective of enterprise, innovation become more and more enterprise development strategy, the corresponding also obtain more resources matching, such as 18 in this year's list of top 20 enterprises in the annual report disclosure of the r&d, development costs 9.994 billion yuan in 2017, including hengrui pharmaceutical r&d costs 1.759 billion yuan in 2017, 12.71% of its main business income.
In terms of the research and development model, as the division of labor in the research and development chain becomes more and more refined, r&d outsourcing, cooperative r&d and overseas cooperation are widely favored by enterprises, so as to improve the efficiency of research and development and share the risks of enterprises. Fosun, for example, is currently developing seven new drugs in its own research and development, and is in partnership with multinational pharmaceutical company kitkite Pharma to introduce kitkite Pharma's car-t treatment product kte-c19 to treat b-cell lymphoma.
The field of biopharmaceutics is promising
China's biopharmaceutical industry started late, but has developed rapidly in recent years with the strong support of the national industrial policy, which is widely regarded as the most valuable medical subdivision in the industry.
On the one hand, the traditional pharmaceutical companies such as hengrui, fosun, method, yasuhiro miyata, million sails pharmaceutical, green leaves, such as layout of biological medicine field, for example, once the main innovation is research and development focus on the leaves of the pharmaceutical chemical medicine to shandong at the end of 2017 pa biological buy two single drug resistance - restructuring really humanized monoclonal antibody injection (LY01008) and recombinant monoclonal antibody against RANKL being injection (LY06006), and announced in March this year with the United States of California biotechnology company Excel Biopharm LLC, The development of therapeutic antibodies for the next generation of tumor immunotherapy will use the unique rabbit monoclonal antibody platform of Excel Biopharm to screen and find antibodies for specific targets, so as to enrich the relevant biological drugs of luye group, and take charge of the market development and commercial operation of all candidate drugs.
On the other hand, a number of domestic outstanding biopharmaceutical enterprises rapidly rise to become the industry leader, now the first time on the list of sansheng pharmaceuticals. In 2017, sansheng pharmaceutical's revenue was 3.734 billion yuan, and its net profit was about 815 million yuan, with a compound growth rate of 49.4% and 49.95%. As a pioneer in China's biopharmaceutical industry, the company's core products are all market leaders in the market segment: tibiao is a recombinant human thrombopoietin for the treatment of thrombocytopenia, with a market share of about 51% in 2017. Yisep is a tumor necrosis factor inhibitor, which is used for the treatment of wind-like and ankylosing spondylitis, with a market share of 60.4%. Two recombinant human erythrin products, ipbio and cybertron, had 41.6 per cent of the market. The company actively develops new drugs. By the end of 2017, 31 new drugs are being developed, including nephropathy, tumor, autoimmunity, diabetes and dermatology, etc.
In addition to independent research and development, the rapid development of sansheng pharmaceutical cannot be separated from extensive mergers and acquisitions. Acquisition of China citic guojian to gain benefits of the sai pu and in the development of a single anti-drug and production platform; Conclude with astrazeneca exclusive license agreement, obtain Ⅱ diabetes drugs Bydureon and Byetta in China's commercial rights; In cooperation with Biotechnologies, Inc., the company has obtained the exclusive license of the california-controlled cell therapy in greater China.
Brand and culture
Traditional Chinese medicine (TCM) is an important part of China's traditional culture. In recent years, with the frequent release of Chinese medicine policies, the state has promoted it as a pillar industry. In retrospect, yunnan baiyao, donga jiao, tongrentang and other enterprises with profound Chinese medicine brand culture have been listed many times. Centering on "yunnan baiyao", the central product of yunnan baiyao, yunnan baiyao has been constantly innovating and expanding, advancing into the field of daily use, laying out the great health industry, and expanding its brand advantages from drugs to health products and great health fields. Tongrentang is an old name in China, and its ancient motto, "though the processing is complicated, it must not save manpower, and taste is expensive, it must not reduce material resources" is the best interpretation of the brand culture of tongrentang, and it is also an important factor for tongrentang to gain recognition from consumers and respect from competitors. In recent years, donga gum has been continuously developing its culture, enhancing its brand strength, and using cultural marketing to lead the return of its value. In the process of integrating industrial chain resources and strengthening industrial potential, the brand culture and the brand power behind it are the powerful guarantee for its continuous progress.